Soft-tissue sarcomas(STS)represent a group of rare and heterogeneous tumors associated with several challenges,including incorrect or late diagnosis,the lack of clinical expertise,and limited therapeutic options.Digit...Soft-tissue sarcomas(STS)represent a group of rare and heterogeneous tumors associated with several challenges,including incorrect or late diagnosis,the lack of clinical expertise,and limited therapeutic options.Digital pathology and radiomics represent transformative technologies that appear promising for improving the accuracy of cancer diagnosis,characterization and monitoring.Herein,we review the potential role of the application of digital pathology and radiomics in managing patients with STS.We have particularly described the main results and the limits of the studies using radiomics to refine diagnosis or predict the outcome of patients with soft-tissue sarcomas.We also discussed the current limitation of implementing radiomics in routine settings.Standard management approaches for STS have not improved since the early 1970s.Immunotherapy has revolutionized cancer treatment;nonetheless,immuno-oncology agents have not yet been approved for patients with STS.However,several lines of evidence indicate that immunotherapy may represent an efficient therapeutic strategy for this group of diseases.Thus,we emphasized the remarkable potential of immunotherapy in sarcoma treatment by focusing on recent data regarding the immune landscape of these tumors.We have particularly emphasized the fact that the development of immunotherapy for sarcomas is not an aspect of histology(except for alveolar soft-part sarcoma)but rather that of the tumor microenvironment.Future studies investigating immunotherapy strategies in sarcomas should incorporate at least the presence of tertiary lymphoid structures as a stratification factor in their design,besides including a strong translational program that will allow for a better understanding of the determinants involved in sensitivity and treatment resistance to immune-oncology agents.展开更多
Dear Editor,Surgery remains the cornerstone of treatment for softtissue sarcomas(STS)[1].However,despite adequate locoregional treatment,30%-40%of the patients eventually develop metastases[2,3].Accurate risk assessme...Dear Editor,Surgery remains the cornerstone of treatment for softtissue sarcomas(STS)[1].However,despite adequate locoregional treatment,30%-40%of the patients eventually develop metastases[2,3].Accurate risk assessment is crucial to tailor therapeutic strategies and to identify high-risk patients who may benefit from perioperative chemotherapy.Hence,several efforts have been made to develop prognostic nomograms that enable individual prognosis prediction;representing an important decision-making aid for oncologists and surgeons involved in sarcoma care[4-6].展开更多
基金Agence Nationale de la Recherche-Recherche Hospitalo-Universitaire en sante(RHU)CONDOR programme。
文摘Soft-tissue sarcomas(STS)represent a group of rare and heterogeneous tumors associated with several challenges,including incorrect or late diagnosis,the lack of clinical expertise,and limited therapeutic options.Digital pathology and radiomics represent transformative technologies that appear promising for improving the accuracy of cancer diagnosis,characterization and monitoring.Herein,we review the potential role of the application of digital pathology and radiomics in managing patients with STS.We have particularly described the main results and the limits of the studies using radiomics to refine diagnosis or predict the outcome of patients with soft-tissue sarcomas.We also discussed the current limitation of implementing radiomics in routine settings.Standard management approaches for STS have not improved since the early 1970s.Immunotherapy has revolutionized cancer treatment;nonetheless,immuno-oncology agents have not yet been approved for patients with STS.However,several lines of evidence indicate that immunotherapy may represent an efficient therapeutic strategy for this group of diseases.Thus,we emphasized the remarkable potential of immunotherapy in sarcoma treatment by focusing on recent data regarding the immune landscape of these tumors.We have particularly emphasized the fact that the development of immunotherapy for sarcomas is not an aspect of histology(except for alveolar soft-part sarcoma)but rather that of the tumor microenvironment.Future studies investigating immunotherapy strategies in sarcomas should incorporate at least the presence of tertiary lymphoid structures as a stratification factor in their design,besides including a strong translational program that will allow for a better understanding of the determinants involved in sensitivity and treatment resistance to immune-oncology agents.
文摘Dear Editor,Surgery remains the cornerstone of treatment for softtissue sarcomas(STS)[1].However,despite adequate locoregional treatment,30%-40%of the patients eventually develop metastases[2,3].Accurate risk assessment is crucial to tailor therapeutic strategies and to identify high-risk patients who may benefit from perioperative chemotherapy.Hence,several efforts have been made to develop prognostic nomograms that enable individual prognosis prediction;representing an important decision-making aid for oncologists and surgeons involved in sarcoma care[4-6].
